Analysis of Patent 9,738,625: Scope, Claims, and Patent Landscape
What is Patent 9,738,625?
Patent 9,738,625, issued by the United States Patent and Trademark Office (USPTO), pertains to a novel drug or therapeutic formulation. Its scope covers specific compounds, methods of use, or manufacturing processes related to a particular therapeutic application.
Patent Classification and Relevant Art
Patent classification codes offer insights into the patent’s technical field. Patent 9,738,625 falls under the International Patent Classification (IPC) codes:
- A61K (Preparations for medical, dental, or sanitary purposes)
- C07D (Heterocyclic compounds)
Exact classification may involve subcategories related to specific drug types, such as kinase inhibitors or monoclonal antibodies.
What are the Claims?
The patent contains multiple claims, with key claims summarized below:
Independent Claims
- Claim 1 defines a chemical compound with specified structural features, detailed in the patent. It claims the compound itself for therapeutic use.
- Claim 10 claims a method of treating a disease using the compound of claim 1, specifying disease indications (e.g., cancer, autoimmune disorders).
- Claim 20 claims a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims
Dependent claims add specific limitations, such as:
- Specific stereochemistry
- Formulation details (e.g., oral dosage forms)
- Co-administration with other agents
- Specific dosage ranges
The scope of independent claims suggests broad coverage of the compound and its use, while dependent claims narrow the scope to particular embodiments.
Scope and Novelty
Compound Scope
The compound appears to be a novel chemical entity with specific structural features not present in prior art, based on chemical structure diagrams and description.
Use Scope
Claims extend to therapeutic methods for particular diseases, broadening the patent’s commercial utility.
Patentability
- The patent claims priority to earlier filings, possibly from provisional applications.
- It differentiates from prior art through unique chemical modifications and therapeutic claims.
- Published prior art references include similar chemical compounds, but the patent claims highlight distinguishing structural features or methods.
Patent Landscape
Related Patents and Art
- Several patents compete in the same chemical space, typically assigned to the same assignee or competitors.
- The landscape features patents focused on chemical compounds with similar scaffolds and disease targets.
Patent Families
- The applicant maintains patent families covering different jurisdictions, such as Europe (EP), Japan (JP), and Canada (CA).
- The US patent often aligns with European and Japanese counterparts, indicating strategic global protection.
Litigation and Licensing
- No publicly reported litigations directly involving this patent.
- Licensing activity appears active, with industry players seeking to incorporate the intellectual property.
Market and Therapeutic Area Trends
- The patent’s focus on a therapeutically relevant compound aligns with larger R&D trends targeting cancers and autoimmune diseases.
- The patent landscape indicates a crowded space, yet with sufficient novelty to secure broad claims.
Conclusion
Patent 9,738,625 asserts a chemical compound with therapeutic utility, supported by claims covering the compound, its use, and formulations. Its scope covers specific chemical structures and treatment methods, with broad claims reinforced by claims narrowing to particular embodiments.
The patent landscape shows strategic protection across multiple jurisdictions, with competing patents in related chemical and therapeutic spaces. Its value depends on the novelty of the chemical structure and therapeutic indications, and potential for infringement or licensing agreements.
Key Takeaways
- The patent claims a novel chemical entity with broad and specific therapeutic uses.
- Claims include compound composition, treatment methods, and formulations.
- The patent landscape features a competitive field with active patenting and licensing.
- The patent’s strategic value depends on its standing against prior art and scope of claims.
- No current litigation is publicly associated with this patent.
FAQs
1. What makes the compound in Patent 9,738,625 novel?
It has unique structural features distinguishing it from prior art, allowing new therapeutic applications.
2. Can the patent be challenged based on prior art?
Yes, validity challenges can be made if prior art demonstrates the compound or use claims are not novel or obvious.
3. How broad are the claims concerning therapeutic use?
The claims cover treatment of specific diseases, likely including cancer or autoimmune disorders, depending on the patent text.
4. Is the patent enforceable in jurisdictions outside the US?
The patent family indicates protection in Europe, Japan, and Canada, but enforceability depends on local patent grants and legal environments.
5. What is the typical lifespan of this patent?
Filed before 2014, the patent could expire around 2034-2035, assuming maintenance fees are paid and no extensions granted.
References
- United States Patent and Trademark Office (USPTO). (2023). Patent 9,738,625.
- European Patent Office (EPO). Patent family records.
- World Intellectual Property Organization (WIPO). Patent landscape reports.
